TACE (transarterial chemoembolization) combined with targeted/immunotherapy

DRUG4 trials

Sponsors

Fudan University, Wei Zhang, Binkui Li, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions

Hepatocellular CarcinomaHepatocellular Carcinoma (HCC)Unresectable Hepatocellular Carcinoma

Phase 2

Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma

RecruitingNCT07154082

Wei ZhangHepatocellular Carcinoma (HCC)

Start: 2025-12-30End: 2028-07-31Target: 27Updated: 2025-09-04

Phase 3

HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)

RecruitingNCT07594340

Binkui LiHepatocellular Carcinoma

Start: 2026-05-15End: 2030-05-30Target: 300Updated: 2026-05-22

Unknown Phase

A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer

Not yet recruitingNCT05660213

Fudan UniversityUnresectable Hepatocellular Carcinoma

Start: 2025-08-31End: 2030-08-31Target: 750Updated: 2025-05-20

TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC

RecruitingNCT07658833

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityHepatocellular Carcinoma (HCC)

Start: 2026-07-01End: 2028-06-30Target: 120Updated: 2026-06-22